ABBV
ABBV — Healthcare
Graham: 12
Buffett: 68
Lynch: 14
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients...
Price ?
207.18
Market Cap ?
366.3B
P/E ?
87.79
P/B ?
-111.99
Div Yield ?
3.21%
52W Range ?
164.39 - 244.81
200W MA ?
164.86
12
Graham-style buying rate (0-100)
Criteria breakdown
- ✓ Company size sufficient (large-cap) ? $366,329,233,408 — Uses market cap >= $2B as proxy
- ✗ Solid financial condition (CR>=2; LT debt <= NCAV) ? CR=0.67 | D/E=? — Partial: checks current ratio; LT debt vs NCAV unavailable
- ✗ Uninterrupted dividends for 20 years ?
- ✗ No losses in last 10 years ? 10y window
- ✗ EPS growth >= 33% over 10 years ? ~20%
- ✗ Price-to-Book (P/B) <= 1.5 ? -111.99
- ✗ Price-to-Earnings (P/E) <= 15 ? 87.8 — Uses trailing P/E as proxy for 3y avg EPS
- ✗ Combined formula (P/E * P/B) <= 22.5 ? — Needs positive P/E and P/B
- ✗ Margin of safety >= 20% ? -1254% — Intrinsic via 5y avg EPS * 15
- ? High ROE maintained without excessive debt ? ROE=62.2% | D/E=? — Approximate threshold ROE = 15%, D/E = 1.0
What is evaluated (Graham):
- Valuation discipline and buying below intrinsic value.
- Financial resilience: liquidity and prudent leverage.
- Consistent dividends and earnings over long horizons.
"The intelligent investor is a realist who sells to optimists and buys from pessimists." — Benjamin Graham
68
Buffett-style buying rate (0-100)
Criteria breakdown
- ✓ Positive and growing FCF (multi-year) ? 19,780,000,000 -> 20,244,000,000
- ✓ ROIC >= 12% sustained ? 23.5%
- ✓ High ROE (proxy for durable advantages) ? 62.2% — Consistency over years not checked
- ✗ Net profit margin >= 10% ? 6.9% — Derived from available financial filings
- ? Conservative leverage (D/E <= 1.0) ? — No D/E data
- ✓ Sustainable shareholder returns (dividend > 0%) ? 3.21% — Does not assess buybacks or payout safety
What is evaluated (Buffett):
- Durable advantages: high ROE, healthy margins.
- Balance discipline and shareholder friendly capital use.
- Positive free cash flow and efficient reinvestment.
"It is far better to buy a wonderful company at a fair price than a fair company at a wonderful price." — Warren Buffett
14
Lynch-style buying rate (0-100)
Criteria breakdown
- ? PEG ratio (P/E / growth) <= 1.0 ? — needs positive EPS growth
- ? Positive multi-year EPS growth (per-year >= 10%) ? — Requires positive EPS history
- ? Conservative leverage (D/E <= 0.5) ? — No D/E data
- ✓ Sustainable profitability (net margin >= 5%) ? 6.9%
- ✗ Earnings stability (no losses in 10y) ? 10y window
What is evaluated (Lynch):
- Growth at a reasonable price (PEG and EPS CAGR).
- Durable earnings with limited drawdowns.
- Conservative balance sheet and baseline profitability.
"Know what you own, and know why you own it." — Peter Lynch